High Plasma Levels of Neuropeptide Y Correlate With Good Clinical Outcome But are not Correlated to Cerebral Blood Flow or Vasospasm After Subarachnoid Hemorrhage

Abstract

Our findings in peripheral blood were not supportive of a causal relationship between NPY secretion and DCI. Although high levels of plasma-NPY were correlated with good clinical outcome, NPY did not show promise as a clinically useful biomarker.

Both coiling and clipping induce the time-dependent release of endogenous neuropeptide Y into serum

“…Considering these multifaceted interrelations, our findings raise the interesting question of whether NPY overexpression following cerebrovascular manipulation might affect the cognitive, psychobehavioral, or emotional outcome of patients with cerebrovascular malformation, which appears all the more feasible against this background. In accordance with psychobehavioral literature on NPY (12, 16,19,26,27,56), neurovascular patients with elevated postprocedural NPY concentrations might theoretically have a more favorable cognitive and neuropsychological prognosis than patients with persistently low NPY levels or with a delayed NPY increase several days after the respective treatment maneuver. To date, the behavioral profile of the action of NPY has insufficiently been characterized, though, with no data available on patients with cerebrovascular malformations.…”

“…The onset of migraine was attributed to a dysregulation of its antagonistic interaction with vasodilatative neuropeptides (15). Additionally, in basic and clinical experimental research on subarachnoid hemorrhage (SAH) in animal models and in humans, NPY has repeatedly shown to be excessively released into the cerebrospinal fluid (CSF) and into serum (16)(17)(18)(19)(20)(21)(22). Compared to other types of intracranial hemorrhage, we observed an increased release of NPY into CSF to be specific for SAH (21).…”

“…Since the early 1990ies, several authors scrutinized the (pathophysiological) interrelations of SAH with the potent vasoconstrictor NPY, and its impact on CV, consecutive cerebral ischemia, and, due to its multiple intrinsic and psychoactive properties, on neurobehavioral outcome in experimental animal models as well as in humans [ cf. ( 22 ) and ( 21 ) and references within]: Considering NPY to be a promising biomarker in neuroscience and, predominantly, in SAH, it was tracked in remarkable concentrations immunohistochemically in the perivascular nerve fibers of the major cerebral arteries ( 25 ) and in the supratentorial dura mater ( 24 ), respectively, in CSF ( 16 – 18 , 21 , 22 , 37 ), and in the external jugular vein/serum ( 17 , 19 – 21 , 37 ). The question of how cerebrovascular manipulation can exert proven neuropeptidergic changes is a matter of speculation ( cf.…”

“…The vascular and the non-vascular group of our cohort did not vary in terms of their functional outcome (as to the GOS and mRS). In patients with aneurysmal SAH, NPY was proposed as a possible positive predictor of outcome ( 16 , 19 ). In contrast, in 2018, we found upregulated NPY levels after SAH, related to poorer hrQoL (as to psychological health, depression, anxiety and nutrition disorder) ( 22 ).…”

Curative effect of minimally invasive puncture and drainage assisted with alteplase on treatment of acute intracerebral hemorrhage

“…NPY mainly distributes in the neuron and its neurite, and it is involved with the regulation and control of the sympathetic nerve system activity. The damage of neuron and spongiocyte will lead to a release of the above molecules into blood circulation [24,25]. IMA is a product of the combination of albumin under hypoxic-ischemic condition with divalent metal ion.…”